Literature DB >> 8727100

Integrin alpha V beta 3 expression by bone-residing breast cancer metastases.

H Liapis1, A Flath, S Kitazawa.   

Abstract

Breast cancer metastasis to bone is a multistep process requiring attachment of tumor cells to the bone and bone marrow environment. The precise adhesion molecules involved in skeletal homing of breast cancer to bone are unknown but likely include integrins. We investigated the expression of vitronectin receptor (alpha V beta 3) by breast cancer cells residing in bone because this heterodimer mediates osteoclast-bone recognition. We used immunohistochemistry and in situ hybridization in a systematic study of 22 bone biopsies containing breast cancer metastases and available samples of corresponding primary tumors and normal breast and compared alpha V beta 3, alpha 2 beta 1, and alpha B beta 5 integrin expression. The results showed that alpha V beta 3 was strongly expressed by normal breast epithelium and was decreased in some and strongly expressed in other primary invasive breast carcinomas. In contrast, this integrin heterodimer was abundant in all breast cancer cells metastatic to bone. In situ hybridization revealed high levels of steady-state mRNA corresponding to sites of protein expression; alpha 2 beta 1 was weakly expressed in both primary and metastatic tumors, and alpha V beta 5 was not detected. Our results showed an overexpression of alpha V beta 3 by bone-residing breast cancer cells and suggest either subclonal selection of alpha V beta 3-expressing tumor cell populations or upregulation of alpha V beta 3 in the bone microenvironment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8727100     DOI: 10.1097/00019606-199606000-00008

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  62 in total

1.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.

Authors:  Yuan Liu; Krishna Mohan Bajjuri; Cheng Liu; Subhash C Sinha
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

3.  Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Lutz Edler; Jan Lubinski; Rodney J Scott; Ute Hamann
Journal:  J Med Genet       Date:  2007-01-12       Impact factor: 6.318

4.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2010-11-01       Impact factor: 5.285

Review 5.  Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?

Authors:  Nayoung Lee; Steven R Barthel; Tobias Schatton
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

6.  Alphav integrins mediate adhesion and migration of breast carcinoma cell lines.

Authors:  N C Wong; B M Mueller; C F Barbas; P Ruminski; V Quaranta; E C Lin; J W Smith
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

7.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

8.  Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.

Authors:  Jing Y Krzeszinski; Adam G Schwaid; Wing Yin Cheng; Zixue Jin; Zachary R Gallegos; Alan Saghatelian; Yihong Wan
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

9.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

10.  Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Authors:  Michael H Ross; Alison K Esser; Gregory C Fox; Anne H Schmieder; Xiaoxia Yang; Grace Hu; Dipanjan Pan; Xinming Su; Yalin Xu; Deborah V Novack; Thomas Walsh; Graham A Colditz; Gabriel H Lukaszewicz; Elizabeth Cordell; Joshua Novack; James A J Fitzpatrick; David L Waning; Khalid S Mohammad; Theresa A Guise; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2017-08-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.